» Articles » PMID: 38158297

Development of COVID-19 Vaccine Policy - United States, 2020-2023

Abstract

COVID-19 vaccines represent a great scientific and public health achievement in the face of overwhelming pressures from a global pandemic, preventing millions of hospitalizations and deaths due to COVID-19 vaccines in the United States. Over 675 million doses of COVID-19 vaccines have been administered in the United States, and over 80% of the U.S. population has had at least 1 dose of a COVID-19 vaccine. Over the course of the COVID-19 pandemic in the United States, over one million people died from COVID-19, and over six million were hospitalized. It has been estimated that COVID-19 vaccines prevented more than 18 million additional hospitalizations and more than 3 million additional deaths due to COVID-19 in the United States. From the beginning of the COVID-19 pandemic in 2020 through June 2023, ACIP had 35 COVID-19 focused meetings and 24 votes for COVID-19 vaccine recommendations. ACIP had the critical task of rapidly and thoroughly reviewing emerging and evolving data on COVID-19 epidemiology and vaccines, as well as making comprehensive population-based recommendations for vaccine policy and considerations for implementation through a transparent and evidence-based framework. Safe and effective COVID-19 vaccines, recommended through transparent policy discussions with ACIP, remain the best tool we have to prevent serious illness, hospitalization and death from COVID-19.

Citing Articles

Pharmacists' answer to the COVID-19 pandemic: Contribution of the Federal Retail Pharmacy Program to COVID-19 vaccination across sociodemographic characteristics-United States.

El Kalach R, Jones-Jack N, Grabenstein J, Elam M, Olorukooba A, deMartino A J Am Pharm Assoc (2003). 2024; 65(1):102305.

PMID: 39615591 PMC: 11839327. DOI: 10.1016/j.japh.2024.102305.


COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.

Markowitz L, Hopkins Jr R, Broder K, Lee G, Edwards K, Daley M Vaccine. 2024; 42 Suppl 3:125549.

PMID: 38341293 PMC: 11310362. DOI: 10.1016/j.vaccine.2023.12.059.


Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.

Link-Gelles R, Britton A, Fleming-Dutra K Vaccine. 2023; 42 Suppl 3:125492.

PMID: 38129285 PMC: 11304400. DOI: 10.1016/j.vaccine.2023.12.002.

References
1.
Frenck Jr R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S . Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239-250. PMC: 8174030. DOI: 10.1056/NEJMoa2107456. View

2.
Amirthalingam G, Lopez Bernal J, Andrews N, Whitaker H, Gower C, Stowe J . Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021; 12(1):7217. PMC: 8664823. DOI: 10.1038/s41467-021-27410-5. View

3.
Fleming-Dutra K, Wallace M, Moulia D, Twentyman E, Roper L, Hall E . Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(26):859-868. DOI: 10.15585/mmwr.mm7126e2. View

4.
Creech C, Anderson E, Berthaud V, Yildirim I, Atz A, Melendez Baez I . Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. N Engl J Med. 2022; 386(21):2011-2023. PMC: 9127699. DOI: 10.1056/NEJMoa2203315. View

5.
Carson S, Casillas A, Castellon-Lopez Y, Mansfield L, Morris D, Barron J . COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California. JAMA Netw Open. 2021; 4(9):e2127582. PMC: 8485164. DOI: 10.1001/jamanetworkopen.2021.27582. View